Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Cabozantinib in Metastatic TNBC
NCT03316586Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, cabozantinib in triple-negative breast cancer (TNBC), sponsored by Dana-Farber Cancer Institute. Started Nov 2017; status: completed.
02
Drugs
nivolumabcabozantinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03316586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03316586.